Clinical trials: Computed Tomography
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia
- Trial name
- NCT02143414
- Testing
- Biopsy Procedure, Biospecimen Collection, Blinatumomab
- Where
- 195 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of budesonide may keep lung cancer from forming in patients with lung nodules.
- Trial name
- NCT00321893
- Testing
- Budesonide
- Where
- Italy
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
Dementia
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved.
- Trial name
- NCT03958630
- Testing
- 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT05756166
- Testing
- Biopsy, Biospecimen Collection, Celecoxib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Trial name
- NCT00098813
- Testing
- romidepsin, laboratory biomarker analysis, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
Background: Prostate cancers are difficult to see on most imaging studies such as X-rays, computed tomography (CT) scans, conventional magnetic resonance imaging (MRI) scans and conventional positron emission tomography (PET)…
- Trial name
- NCT00924313
- Testing
- (C-11 Acetate)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions.
- Trial name
- NCT03697551
- Testing
- Satoreotide trizoxetan
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Ipsen
Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia
Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery to remove part or all of their pancreas.
- Trial name
- 18FDOPA (NCT01468454)
- Testing
- 18 F-DOPA
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Children's Hospital of Philadelphia
Brain Cancer
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing.
- Trial name
- NCT01604512
- Testing
- MRI perfusion and PET/CT scans
- Where
- 6 sites in United States
- Volunteers
- 148 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma
- Trial name
- NCT02224781
- Testing
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate
- Where
- 838 sites in United States
- Volunteers
- 267 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT01585805
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Renal Impairment
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.
- Trial name
- CINOPSIS CT (NCT00793182)
- Testing
- Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
- Where
- 13 sites in United States
- Volunteers
- 6 people
- Sponsor
- Guerbet
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients with head and neck squamous cell carcinoma that has spread from where…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02567422
- Testing
- Berzosertib, Cisplatin, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT03348631
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Where
- 581 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Head Trauma, Craniocerebral Injuries
Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas
The goal of this study is to determine the sensitivity, specificity, and positive and negative predictive values of the a portable near-infrared-based device (portable NIR-based device), the InfraScanner 2000™, to detect…
- Conditions
- Head Trauma, Craniocerebral Injuries, Crushing Skull Injury, Head Injuries
- Trial name
- NCT03353246
- Testing
- InfraScanner 2000™
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Duke University
Breast Cancer, HER2-negative Breast Cancer
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Trial name
- NCT04504331
- Testing
- Infigratinib, Tamoxifen, Omnipaque 350
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jennifer Lee Caswell-Jin